TransMedics Group (NASDAQ:TMDX) Shares Gap Down Following Weak Earnings

TransMedics Group, Inc. (NASDAQ:TMDX) shares gapped down before the market opened on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $80.75, but opened at $72.34. TransMedics Group shares last traded at $74.30, with a volume of 847,115 shares traded.

The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.92 earnings per share.

Key Stories Impacting TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Revenue reached $189.95 million, up 20.7% year over year and ahead of the roughly $184 million consensus estimate. TransMedics also raised or reaffirmed full-year 2026 revenue guidance of $737 million to $757 million, above the $733.6 million analyst consensus. TransMedics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company’s earnings call highlighted continued sales growth and demand for its organ-transplant technology. Investors may view the revenue outlook as evidence that TransMedics is maintaining momentum despite near-term earnings pressure. TransMedics Group Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Gross profit increased to $113.2 million, while the company ended the quarter with $472.7 million in cash and equivalents. However, operating cash flow was only $17.3 million and total liabilities rose to $946.3 million, making cash generation and balance-sheet trends worth monitoring. TransMedics Group Stock Rises on Q2 2026 Earnings
• Negative Sentiment: Adjusted earnings came in at approximately $0.44 per share, below the $0.50 consensus estimate and down from $0.92 a year earlier. Operating profit declined 35.1% and net income fell 57.9%, signaling that profitability is lagging revenue growth. TransMedics Earnings Lag Estimates
• Negative Sentiment: Needham issued a pessimistic forecast for TMDX, adding pressure to the stock’s valuation narrative after its sharp decline from the 52-week high. Separately, Rosen Law Firm announced an investigation into potential fiduciary-duty breaches, creating an additional headline and legal risk, although no wrongdoing has been established. Needham Pessimistic Forecast Rosen Law Firm Investigation

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TMDX. UBS Group assumed coverage on shares of TransMedics Group in a research note on Tuesday, July 28th. They set a “neutral” rating and a $80.00 price objective for the company. Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Needham & Company LLC reduced their price objective on TransMedics Group from $142.00 to $106.00 and set a “buy” rating on the stock in a research report on Monday. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Stifel Nicolaus upped their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, June 18th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $126.27.

Insider Buying and Selling

In related news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares in the company, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently modified their holdings of TMDX. D.A. Davidson & CO. grew its holdings in TransMedics Group by 0.5% in the fourth quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock valued at $1,865,000 after purchasing an additional 83 shares during the period. Parallel Advisors LLC grew its stake in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after buying an additional 83 shares during the period. HighPoint Advisor Group LLC increased its holdings in shares of TransMedics Group by 3.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock worth $359,000 after buying an additional 88 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in shares of TransMedics Group by 4.0% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after buying an additional 88 shares during the period. Finally, Canada Pension Plan Investment Board boosted its holdings in TransMedics Group by 2.9% in the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after acquiring an additional 100 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

The stock has a market cap of $2.56 billion, a PE ratio of 16.82 and a beta of 1.90. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. The stock has a 50-day simple moving average of $73.01 and a 200-day simple moving average of $99.72.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.